MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

106.90 -1.02 (-0.95%)
Official Closing Price Updated: 7:00 PM EST, Jan 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
This Stock Is Already Up 58% This Year. Is It a Buy? ↗
This forgotten pandemic stock hasn't said its last word. 
Via The Motley Fool
News headline image
Constitutional Cliffhanger: Supreme Court Set to Rule on Executive Tariff Power as Market Braces for Margin Volatility
As the final days of January 2026 unfold, the financial world is fixed on the steps of the U.S. Supreme Court. A landmark decision in the consolidated cases of Learning Resources, Inc. v. Trump and... 
Via MarketMinute
Topics Economy Government World Trade
News headline image
The $4 Billion Avatar: How Synthesia is Defining the Era of Agentic Enterprise Media
In a landmark moment for the synthetic media landscape, London-based AI powerhouse Synthesia has reached a staggering $4 billion valuation following a $200 million Series E funding round. Announced on... 
Via TokenRing AI
Topics Artificial Intelligence
Merck & Co. Inc. (NYSE:MRK) Stands Out as a High-Quality Dividend Stock ↗
Via Chartmill
MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? ↗
Via Stocktwits
News headline image
FDA Codifies AI’s Role in Drug Production: New 2026 Guidelines Set Global Standard for Pharma Safety and Efficiency
In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial... 
Via TokenRing AI
Topics Artificial Intelligence Economy
News headline image
2 Pharmaceutical Stocks Set to Rebound in 2026 ↗
There might be massive upside ahead for these drugmakers. 
Via The Motley Fool
News headline image
Why Revolution Medicines Stock Plummeted by Almost 17% Today ↗
It doesn't look like the company will end up in the arms of an acquirer soon, after all. 
Via The Motley Fool
News headline image
The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
Revolution Medicines Stock Sinks After Merck Deal Talks Collapse ↗
Merck (NYSE: MRK) reportedly ends discussions to acquire Revolution Medicines (NASDAQ: RVMD) after valuation disagreement. 
Via Benzinga
Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today ↗
Via Stocktwits
Topics Economy Stocks
News headline image
Revolution Medicines Stock Stares At Big Dip After Merck Reportedly Shelves Buyout — But Analyst Flags Opportunity ↗
Stifel expects dip-buyers to step in, saying it would be surprised to see RVMD settle meaningfully below $100, calling the failed talks an “M&A clearing event.” 
Via Stocktwits
News headline image
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗
Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps. 
Via The Motley Fool
Topics ETFs Intellectual Property World Trade
News headline image
2 Dirt Cheap Stocks to Buy With $200 Right Now ↗
These healthcare leaders seem attractive right now. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗
Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing. 
Via The Motley Fool
News headline image
2 Soaring Stocks to Hold for the Next 20 Years ↗
They can power outstanding returns while providing stability to a well-diversified portfolio. 
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026
As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
I Correctly Predicted That These 15 Dow Jones Stocks Would Boost Their Payouts in 2025. Here's Why It Can Happen Again in 2026. ↗
The Dow is chock-full of high-quality companies that pay growing dividends. 
Via The Motley Fool
Topics Stocks
News headline image
Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally
In a landmark moment for the future of personalized medicine, Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) announced groundbreaking five-year follow-up data on January 20, 2026, for... 
Via MarketMinute
Topics Intellectual Property
News headline image
Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth
NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the... 
Via MarketMinute
Topics Earnings Economy Intellectual Property
News headline image
Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse
As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and... 
Via StockStory
Topics Economy Stocks
News headline image
Why Moderna Stock Surged Today ↗
The vaccine maker is expanding beyond its COVID-focused offerings. 
Via The Motley Fool
News headline image
Merck Shares Rise On $30M Funding From CEPI To Develop Affordable Ebola Vaccine ↗
CEPI will provide Merck with $30 million and Merck will, in turn, leverage its joint venture with Wellcome, called Hilleman Laboratories, to develop an Ebola vaccine with an updated manufacturing... 
Via Stocktwits
Topics Workforce
News headline image
Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious ↗
BofA Securities said the target hike reflects higher sales expectations, despite logistics challenges. 
Via Stocktwits
News headline image
Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update ↗
Intismeran autogene vaccine, in combination with cancer drug Keytruda, reduced the risk of recurrence or death at five years of follow-up, the company said. 
Via Stocktwits
News headline image
GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics
In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion.... 
Via MarketMinute
Topics Intellectual Property
News headline image
3 “Forever Stocks” to Hold When the Market Won’t Sit Still ↗
Via MarketBeat
News headline image
The New Era of Johnson & Johnson: A 2026 Deep-Dive Research Feature
As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its... 
Via Finterra
Topics Artificial Intelligence Bankruptcy Economy
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story